Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-24T14:04:32.892Z Has data issue: false hasContentIssue false

Tratamiento combinado de clozapina y litio para la esquizofrenia y el trastorno esquizoafectivo

Published online by Cambridge University Press:  12 May 2020

M. Moldavsky
Affiliation:
Centro de Salud Mental Abarbanel, 15 Keren Kayemet St, Bat- Yam, Israel, afiliado a la Facultad Sackler de Medicina, TelAviv University, TelAviv, lsrael
D. Stein
Affiliation:
Centro de Salud Mental Abarbanel, 15 Keren Kayemet St, Bat- Yam, Israel, afiliado a la Facultad Sackler de Medicina, TelAviv University, TelAviv, lsrael
R. Benatov
Affiliation:
Centro de Salud Mental Abarbanel, 15 Keren Kayemet St, Bat- Yam, Israel, afiliado a la Facultad Sackler de Medicina, TelAviv University, TelAviv, lsrael
P. Sirota
Affiliation:
Centro de Salud Mental Abarbanel, 15 Keren Kayemet St, Bat- Yam, Israel, afiliado a la Facultad Sackler de Medicina, TelAviv University, TelAviv, lsrael
A. Elizur
Affiliation:
Centro de Salud Mental Abarbanel, 15 Keren Kayemet St, Bat- Yam, Israel, afiliado a la Facultad Sackler de Medicina, TelAviv University, TelAviv, lsrael
Y. Matzner
Affiliation:
Unidad de Hematología, Hospital Universitario Hadassah, Mount Scopus, Jerusalem, Israel
A. Weizman
Affiliation:
Hospital Psiquiátrico Geha y Centro Médico Felsenstein, Beilinson Medical Campus, Peath Tiqva, Israel afiliado a la Facultad Sackler de Medicina, TeI Aviv University, Tel Aviv, Israel
Get access

Resumen

Tres adolescentes y dos pacientes adultos que sufrían psicosis crónicas con excitación (esquizofrenia o trastorno esquizoafectivo) resistentes a los neurolépticos tradicionales y a la clozapina recibieron tratamiento con una combinación de clozapina y litio. La mejoría se evaluó con la Escala de Síntomas Positivos y Negativos, la Escala de Evaluación Psiquiátrica Breve y las Impresiones Clínicas Globales, administradas antes y durante el tratamiento combinado de clozapina y litio. Todos los pacientes demostraron una mejoría significativa con esta combinación. No se produjo agranulocitosis, síndrome neuroléptico maligno u otros efectos adversos significativos clínicamente.

Type
Comunicación Breve
Copyright
Copyright © European Psychiatric Association 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.Google Scholar
Baldessarini, RFrankenburg, F.Clozapine. A novel antipsychotic agent. New Engl J Med 1991;324(11):746–54.Google ScholarPubMed
Boggs, DRJoyce, RA.The hematopoietic effects of lit-hium. Semin Hematol 1983;20:129–38.Google Scholar
Brotman, AWFalk, WEGelenberg, AJ.Pharmacologic tre-atment of acute depressive subtypes. In: Meltzer, HY, ed. Psychophamacology. The third generation of progress. New York: Raven Press; 1987:1038.Google Scholar
Bryois, CFerrero, F.Clinical observation of 11 patients under clozapine-lithium association. Eur Psychiatry 1993;8:213–18.CrossRefGoogle Scholar
García, GCrismon, MLDorson, P.Seizures in two patients after the addition of lithium to a clozapine regimen. J Clin Psychopharmacol 1994;14(6):426–7.Google ScholarPubMed
Gerson, SL.Clozapine-deciphering the risks. N Engl J Med 1993;329:204–5.CrossRefGoogle ScholarPubMed
Guy, W.ECDEU Assessment Manual for Psycho-pharmacology. Rockville: US Dept of Health and Human Services Publication (ADM); 1976:218–22.Google Scholar
Hammond, WPDale, DC.Cyclic hematopoiesis: Effects of lithium on colony forming cells and colony stimulating activity in grey collie dogs. Blood 1982;59:179.CrossRefGoogle ScholarPubMed
Hammond, WPRodger, ERDale, DC.Lithium augments GM-CSA generation in canine cyclic hematopoiesis. Blood 1987;69:117–23.CrossRefGoogle ScholarPubMed
Kane, JM.Clinical efficacy of clozapine in treatment-refractory schizophrenia: An overview. Br J Psychiatry 1992;160(suppl 17):41–5.CrossRefGoogle Scholar
Kane, JMHonigfeld, GSinger, J, et al.Clozapine for the treatment-resistant schizophrenic: a double-blind compa-rison with chlorpromazine. Arch Gen Psychiatry 1988;45:789–96.CrossRefGoogle Scholar
Kay, SGOpler, LALindenmayer, JP.Reliability and vali-dity of the Positive and Negative Symptoms Scale for schizophrenia. Psychiatry Res 1988;23:99110.CrossRefGoogle Scholar
Kay, SRWolkenfeld, FMurrill, LM.Profiles of aggression among psychiatric patients. J Nerv Ment Dis 1988;176:547–57.CrossRefGoogle ScholarPubMed
McGrath, HELiang, CMAlberico, TAQuesenberry, PJ.The effect of lithium on growth factor production in long-term bone marrow cultures. Blood 1987;70:1136–42.CrossRefGoogle ScholarPubMed
Naber, DHolzbach, RPerro, CHippius, H.Clinical mana-gement of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 1992;160(suppl 17):54–9.CrossRefGoogle Scholar
Overall, JEGorham, DR.The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799812.CrossRefGoogle Scholar
Pope, HG JrCole, JOChoras, PTFulwiler, CF.Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986;174(8):493–5.CrossRefGoogle ScholarPubMed
Sandoz Pharma Ltd. Clozaril, new drug application. East Hanover: Sandoz Pharma Ltd; 1987.Google Scholar
Valevski, AModai, ILahav, MWeizman, A.Clozapine-lit-hium combined treatment and agranulocytosis. Int Clin Pharmacol 1993;8:63–5.Google ScholarPubMed